Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer

Dan-Dan Zhou; Wei-Qi Bai; Xiao-Tian Zhai; Li-Ping Sun; Yong-Su Zhen; Zhuo-Rong Li; Qing-Fang Miao

doi:10.1186/s40779-021-00358-9

Your Location：

Home >

Browse articles >

Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer

RESEARCH | Updated：2023-02-28

- Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
- Military Medical Research Vol. 9, Issue 4, Pages: 419-431(2022)
- Affiliations：
  
  1.NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Tiantan Xili, Beijing 100050, China
  2.Department of Organic Chemistry, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Tiantan Xili, Beijing 100050, China
- Author bio：
  
  * lizhuorong@imb.pumc.edu.cn;
  miaoqf@imb.pumc.edu.cn
- Funds：
- DOI：10.1186/s40779-021-00358-9
  CLC：
- Published：2022-08
- Accepted：
Scan QR Code
Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, et al. Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer. Mil Med Res. 2021;8(1):63.
DOI：

Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, et al. Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer. Mil Med Res. 2021;8(1):63. DOI： 10.1186/s40779-021-00358-9.

摘要

Abstract

Background:

Triple-negative breast cancer (TNBC) is the most aggressive subtype and occurs in approximately 15%–20% of diagnosed breast cancers. TNBC is characterized by its highly metastatic and recurrent features

as well as a lack of specific targets and targeted therapeutics. Epidermal growth factor receptor (EGFR) is highly expressed in a variety of tumors

especially in TNBC. LR004-VC-MMAE is a new EGFR-targeting antibody–drug conjugate produced by our laboratory. This study aimed to evaluate its antitumor activities against EGFR-positive TNBC and further studied its possible mechanism of antitumor action.

Methods:

LR004-VC-MMAE was prepared by coupling a cytotoxic payload (MMAE) to an anti-EGFR antibody (LR004)

via

a linker

and the drug-to-antibody ratio (DAR) was analyzed by HIC-HPLC. The gene expression of EGFR in a series of breast cancer cell lines was assessed using a publicly available microarray dataset (GSE41313) and Western blotting. MDA-MB-468 and MDA-MB-231 cells were treated with LR004-VC-MMAE (0

0.0066

0.066

0.66

6.6 nmol/L)

and the inhibitory effects of LR004-VC-MMAE on cell proliferation were examined by CCK-8 and colony formation. The migration and invasion capacity of MDA-MB-468 and MDA-MB-231 cells were tested at different LR004-VC-MMAE concentrations (2.5 and 5 nmol/L) with wound healing and Transwell invasion assays. Flow cytometric analysis and tumorsphere-forming assays were used to detect the killing effects of LR004-VC-MMAE on cancer stem cells (MDA-MB-468 and MDA-MB-231 cells). The mouse xenograft models were also used to evaluate the antitumor efficacy of LR004-VC-MMAE

in vivo

. Briefly

BALB/c nude mice were subcutaneously inoculated with MDA-MB-468 or MDAMB-231 cells. Then they were randomly divided into 4 groups (

=6 per group) and treated with PBS

naked LR004 (10 mg/kg)

LR004-VC-MMAE (10 mg/kg)

or doxorubicin

respectively. Tumor sizes and the body weights of mice were measured every 4 d. The effects of LR004-VC-MMAE on apoptosis and cell cycle distribution were analyzed by flow cytometry. Western blotting was used to detect the effects of LR004-VC-MMAE on EGFR

ERK

MEK phosphorylation and tumor stemness marker gene expression.

Results:

LR004-VC-MMAE with a DAR of 4.02 were obtained. The expression of EGFR was found to be significantly higher in TNBC cells compared with non-TNBC cells (

0.01). LR004-VC-MMAE inhibited the proliferation of EGFR-positive TNBC cells

and the IC

values of MDA-MB-468 and MDA-MB-231 cells treated with LR004-VC-MMAE for 72 h were (0.13±0.02) nmol/L and (0.66±0.06) nmol/L

respectively

which were significantly lower than that of cells treated with MMAE [(3.20±0.60) nmol/L

0.01

and (6.60±0.50) nmol/L

0.001]. LR004-VC-MMAE effectively inhibited migration and invasion of MDA-MB-468 and MDA-MB-231 cells. Moreover

LR004-VC-MMAE also killed tumor stem cells in EGFR-positive TNBC cells and impaired their tumorsphere-forming ability. In TNBC xenograft models

LR004-VC-MMAE at 10 mg/kg significantly suppressed tumor growth and achieved comple

te tumor regression on day 36. Surprisingly

tumor recurrence was not observed until the end of the experiment on day 52. In a mechanistic study

we found that LR004-VC-MMAE significantly induced cell apoptosis and cell cycle arrest at G

/M phase in MDAMB-468 [(34±5)%

. (12±2)%

0.001] and MDA-MB-231 [(27±4)%

. (18±3)%

0.01] cells. LR004-VC-MMAE also inhibited the activation of EGFR signaling and the expression of cancer stemness marker genes such as Oct4

Sox2

KLF4 and EpCAM.

Conclusions:

LR004-VC-MMAE showed effective antitumor activity by inhibiting the activation of EGFR signaling and the expression of cancer stemness marker genes. It might be a promising therapeutic candidate and provides a potential therapeutic avenue for the treatment of EGFR-positive TNBC.

关键词

Keywords

references

Medina MA , Oza G , Sharma A , Arriaga LG , Hernández Hernández JM , Rotello VM , et al . Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies . Int J Environ Res Public Health . 2020 ; 17 ( 6 ): 2078 .

Yin L , Duan JJ , Bian XW , Yu SC . Triple-negative breast cancer molecular subtyping and treatment progress . Breast Cancer Res . 2020 ; 22 ( 1 ): 61 .

Vagia E , Mahalingam D , Cristofanilli M . The landscape of targeted therapies in TNBC . Cancers (Basel) . 2020 ; 12 ( 4 ): 916 .

Puri A , Reddy TP , Patel TA , Chang JC . Metastatic triple-negative breast cancer: established and emerging treatments . Breast J . 2020 ; 26 ( 9 ): 1793 - 6 .

Wu M , Zhang P . EGFR-mediated autophagy in tumourigenesis and therapeutic resistance . Cancer Lett . 2020 ; 469 : 207 - 16 .

Hoadley KA , Weigman VJ , Fan C , Sawyer LR , He X , Troester MA , et al . EGFR associated expression profiles vary with breast tumor subtype . BMC Genom . 2007 ; 8 : 258 .

Pancewicz-Wojtkiewicz J . Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer . Cancer Med . 2016 ; 5 ( 12 ): 3572 - 8 .

Byrne M , Saif MW . Selecting treatment options in refractory metastatic colorectal cancer . OncoTargets Ther . 2019 ; 12 : 2271 - 8 .

Verma HK , Kampalli PK , Lakkakula S , Chalikonda G , Bhaskar LVKS , Pattnaik S . A retrospective look at anti-EGFR agents in pancreatic cancer therapy . Curr Drug Metab . 2019 ; 20 ( 12 ): 958 - 66 .

Masuda H , Zhang D , Bartholomeusz C , Doihara H , Hortobagyi GN , Ueno NT . Role of epidermal growth factor receptor in breast cancer . Breast Cancer Res Treat . 2012 ; 136 ( 2 ): 331 - 45 .

Nakai K , Hung MC , Yamaguchi H . A perspective on anti-EGFR therapies targeting triple-negative breast cancer . Am J Cancer Res . 2016 ; 6 ( 8 ): 1609 - 23 .

Tebbutt N , Pedersen MW , Johns TG . Targeting the ERBB family in cancer: couples therapy . Nat Rev Cancer . 2013 ; 13 ( 9 ): 663 - 73 .

Xu Z , Guo D , Jiang Z , Tong R , Jiang P , Bai L , et al . Novel HER2-targeting antibody–drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan (DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985) . Eur J Med Chem . 2019 ; 183 : 111682 .

Chau CH , Steeg PS , Figg WD . Antibody–drug conjugates for cancer . Lancet . 2019 ; 394 ( 10200 ): 793 - 804 .

Khongorzul P , Ling CJ , Khan FU , Ihsan AU , Zhang J . Antibody–drug conjugates: a comprehensive review . Mol Cancer Res . 2020 ; 18 ( 1 ): 3 - 19 .

Kagihara JA , Shagisultanova E , Afghahi A , Diamond JR . Moving towards targeted therapies for triple-negative breast cancer . Curr Breast Cancer Rep . 2021 ; 13 ( 3 ): 216 - 26 .

Nagayama A , Vidula N , Ellisen L , Bardia A . Novel antibody–drug conjugates for triple negative breast cancer . Ther Adv Med Oncol . 2020 ; 12 : 1758835920915980 .

Munasinghe WP , Mittapalli RK , Li H , Hoffman DM , Holen KD , Menon RM , et al . Evaluation of the effect of the EGFR antibody–drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR . Cancer Chemother Pharmacol . 2017 ; 79 ( 5 ): 915 - 22 .

Kang H , Thakar M , Sen R , Chung CH . Antitumor effect of IMGN289, an anti-EGFR antibody–drug conjugate (ADC), in preclinical models of head and neck squamous cell carcinomas (HNSCC) . J Clin Oncol . 2014 ; 32 ( 15_suppl ): e17046 .

Hu XY , Wang R , Jin J , Liu XJ , Cui AL , Sun LQ , et al . An EGFR-targeting antibody–drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies . Mol Oncol . 2019 ; 13 ( 2 ): 246 - 63 .

Kilkenny C , Browne W , Cuthill IC , Emerson M , Altman DG , NC3Rs Reporting Guidelines Working Group . Animal research: reporting in vivo experiments: the ARRIVE guidelines . Br J Pharmacol . 2010 ; 160 ( 7 ): 1577 - 9 .

Denkert C , Liedtke C , Tutt A , von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies . Lancet . 2017 ; 389 ( 10087 ): 2430 - 42 .

McGuinness JE , Kalinsky K . Antibody–drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan . Expert Opin Biol Ther . 2021 ; 21 ( 7 ): 903 - 13 .

Hashimoto Y , Koyama K , Kamai Y , Hirotani K , Ogitani Y , Zembutsu A , et al . A novel HER3-targeting antibody–drug conjugate, U3–1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization . Clin Cancer Res . 2019 ; 25 ( 23 ): 7151 - 61 .

Ocean AJ , Starodub AN , Bardia A , Vahdat LT , Isakoff SJ , Guarino M , et al . Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody–drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics . Cancer . 2017 ; 123 ( 19 ): 3843 - 54 .

You KS , Yi YW , Kwak SJ , Seong YS . Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells . Int J Oncol . 2018 ; 52 ( 3 ): 828 - 40 .

Hsu JL , Hung MC . The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer . Cancer Metastasis Rev . 2016 ; 35 ( 4 ): 575 - 88 . https://doi.org/10.1007/s10555-016-9649-6 https://doi.org/10.1007/s10555-016-9649-6 .

Lim SM , Syn NL , Cho BC , Soo RA . Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies . Cancer Treat Rev . 2018 ; 65 : 1 - 10 .

Wilken JA , Webster KT , Maihle NJ . Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics . J Ovarian Res . 2010 ; 3 : 7 .

Xu MJ , Johnson DE , Grandis JR . EGFR-targeted therapies in the postgenomic era . Cancer Metastasis Rev . 2017 ; 36 ( 3 ): 463 - 73 .

Koganemaru S , Kuboki Y , Koga Y , Kojima T , Yamauchi M , Maeda N , et al . U3–1402, a novel HER3-targeting antibody–drug conjugate, for the treatment of colorectal cancer . Mol Cancer Ther . 2019 ; 18 ( 11 ): 2043 - 50 .

Gan HK , van den Bent M , Lassman AB , Reardon DA , Scott AM . Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells . Nat Rev Clin Oncol . 2017 ; 14 ( 11 ): 695 - 707 .

Peitzsch C , Tyutyunnykova A , Pantel K , Dubrovska A . Cancer stem cells: The root of tumor recurrence and metastases . Semin Cancer Biol . 2017 ; 44 : 10 - 24 .

Ayob AZ , Ramasamy TS . Cancer stem cells as key drivers of tumour progression . J Biomed Sci . 2018 ; 25 ( 1 ): 20 .

Seshacharyulu P , Ponnusamy MP , Haridas D , Jain M , Ganti AK , Batra SK . Targeting the EGFR signaling pathway in cancer therapy . Expert Opin Ther Targets . 2012 ; 16 ( 1 ): 15 - 31 .

Nikolaou M , Pavlopoulou A , Georgakilas AG , Kyrodimos E . The challenge of drug resistance in cancer treatment: a current overview . Clin Exp Metastasis . 2018 ; 35 ( 4 ): 309 - 18 .

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer

Statistical Analysis on Crack Growth Rate of 840D Wheel Web with a Hole

Research on the Measurement System of the Attack Angle between Wheel and Rail Based on Image Identification

Numerical Simulation of 3D Air-Charging Model of the Heavy Haul Train Air Brake Pipes System

Related Author

Qian-Qian Liu

Zi-Kai Dong

Yong-Fei Wang

Wei-Lin Jin

Zaid Sirhan

Anita Thyagarajan

Ravi P. Sahu

Related Institution

Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, the First Hospital of Lanzhou University, the First Clinical Medical College of Lanzhou University

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University

Department of Immunology

Medical School of Xi’an Jiaotong University

⁰